According to the 15-minute chart of Liminatus Pharma, a narrowing of Bollinger Bands and the presence of a bearish Marubozu candle at 13:45 on August 29, 2025 indicate a decrease in the magnitude of stock price fluctuations. This suggests that sellers are currently in control of the market, and the bearish momentum is likely to persist.
Themis Medicare (THEMISMED) has been experiencing significant market fluctuations, with recent data indicating a potential shift in investor sentiment. According to the provided technical analysis, the stock appears to be in a downtrend, with key indicators suggesting a continued bearish momentum. The indicators such as ADX, MACD, and CCI are all generating strong sell signals, while the volume-based indicators are also pointing to a high level of selling activity.
One of the notable aspects of the current market conditions is the narrowing of Bollinger Bands, which suggests a decrease in the magnitude of stock price fluctuations. This narrowing indicates that sellers are currently in control of the market, and the bearish momentum is likely to persist [1].
Additionally, the presence of a bearish Marubozu candle at 13:45 on August 29, 2025, further supports the bearish trend. A Marubozu candle, which has no shadows or wicks, signifies strong market sentiment and can indicate a continuation of the current trend [2].
The stock's price has been consistently below the 20-day Simple Moving Average (SMA) and the middle Bollinger Band, indicating a strong downtrend. The Ichimoku cloud is also of red color, with prices trading below the red cloud, which further confirms the bearish sentiment.
Given the current technical indicators and market conditions, investors should exercise caution when considering investments in Themis Medicare. The strong sell signals and high volume-based selling momentum suggest that the stock may continue to experience downward pressure in the near term.
References:
[1] https://munafasutra.com/nse/stock/THEMISMED
[2] https://munafasutra.com/nse/stock/THEMISMED
Comments
No comments yet